Journal of Psychopharmacology

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

SAGETRACK

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Deakin, J.F.W.
Right arrow Articles by Hellewell, J.S.E.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Deakin, J.F.W.
Right arrow Articles by Hellewell, J.S.E.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Journal of Psychopharmacology, Vol. 11, No. 2, 133-142 (1997)
DOI: 10.1177/026988119701100206

Familial and developmental abnormalities of frontal lobe function and neurochemistry in schizophrenia

J.F.W. Deakin

School of Psychiatry and Behavioural Sciences University of Manchester, Oxford Road, Manchester M13 9WL, UK

M.D.C. Simpson

School of Biological Sciences, University of Manchester, Oxford Road, Manchester M13 9WL, UK

P. Slater

School of Biological Sciences, University of Manchester, Oxford Road, Manchester M13 9WL, UK

J.S.E. Hellewell

School of Psychiatry and Behavioural Sciences University of Manchester, Oxford Road, Manchester M13 9WL, UK

Structural abnormalities of the cerebral cortex in schizophrenia have been revealed by magnetic resonance imaging, although it is not clear whether these abnormalities are diffuse or local. We predicted that changes in cortical structure would result in abnormalities in biochemical markers for the glutamate system in post mortem brain, and that the pattern of neurochemical abnormalities would be a clue to the distribution and extent of pathology. A number of studies have now reported increases in biochemical and other markers of glutamatergic cell bodies and terminals in the frontal cortex in schizophrenia. These findings are consistent with the presence of an abnormally abundant glutamatergic innervation, which may be due to an arrest in the normal developmental process of synaptic elimination. In the anterior temporal cortex and hippocampus there is evidence of an asymmetric loss of glutamate terminals, and of reduced GABA function, which may be secondary to the glutamatergic deficit. Glutamate cell body markers are spared in the temporal lobe; we argue that the loss of glutamate uptake sites may reflect the loss of an extrinsic glutamatergic innervation of the polar temporal cortex which arises from the frontal cortex. These fronto-temporal projections may be vulnerable because they arise from a cytoarchitecture which has not been stabilized by remodelling during early post natal life. There have been several therapeutic studies of drugs with actions on brain glutamate systems. Based on the glutamate deficiency theories, one approach has been to enhance glutamatergic function using agonists of the N-methyl-D-aspartate-linked glycine site. However, there are no clear therapeutic effects, and some studies report aggravation of positive symptoms. This might be expected if, as our post-mortem studies suggested, there is excess glutamatergic innervation in some brain regions in schizophrenia. There is neuropsychological evidence that frontal abnormalities in schizophrenia may be genetically determined. We found that first degree relatives of schizophrenic patients were selectively impaired in tests of frontal lobe function, whereas both frontal and temporal function is impaired in patients. We concluded that the genetic predisposition to schizophrenia involves impaired frontal lobe function. Psychotic symptoms develop only when a second process results in a loss of fronto-temporal projections and leads to temporal lobe dysfunction.

Key Words: frontal lobe • genetics • glutamate • schizophrenia • serotonin • temporal lobe


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J PsychopharmacolHome page
C. H. Large
Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs?
J Psychopharmacol, May 1, 2007; 21(3): 283 - 301.
[Abstract] [PDF]


Home page
Cereb CortexHome page
J. R. Highley, M. A. Walker, M. M. Esiri, T. J. Crow, and P. J. Harrison
Asymmetry of the Uncinate Fasciculus: A Post-mortem Study of Normal Subjects and Patients with Schizophrenia
Cereb Cortex, November 1, 2002; 12(11): 1218 - 1224.
[Abstract] [Full Text] [PDF]